1. First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study.
- Author
-
Chieffo A, Khawaja SA, Vesga B, Hernandez H, Moncada M, Delgado JA, Esposito G, Ferrone M, Dager A, Arana C, Stabile E, Meliga E, De Benedictis M, Montorfano M, Latib A, Fonseca J, Gomez G, Tamburino C, Tarantini G, La Manna A, Maehara A, Granada JF, and Colombo A
- Subjects
- Absorbable Implants, Colombia, Coronary Angiography, Humans, Italy, Molecular Weight, Prospective Studies, Prosthesis Design, Sirolimus, Tomography, Optical Coherence, Treatment Outcome, Cardiovascular Agents therapeutic use, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Coronary Artery Disease surgery, Coronary Restenosis drug therapy, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Abstract
Background: RENASCENT is a prospective, multi-center first-in-human clinical study to evaluate the clinical performance of the novel sirolimus-eluting 150-μm strut thickness FORTITUDE® BRS for percutaneous coronary intervention of single de novo coronary lesions., Methods: FORTITUDE® BRS was tested in a prospective study in Italy and Colombia. Study objectives were in-scaffold angiographic late lumen loss (LLL) measured by quantitative coronary angiography and target vessel failure (TVF) defined as the composite rate of cardiac death, target vessel myocardial infarction or ischemia driven target lesion revascularization (TLR) at 9- and 24-months with clinical results up to 36-months., Results: A total of 63 patients were enrolled. All patients underwent lesion pre-dilatation and 22 patients (34.9%) underwent post-dilatation. Clinical device and procedural success was 98.4% (62/63 patients) and 96.8% (61/63 patients) respectively. At 9-months, TVF occurred in 3/61 (4.9%) of the patients including 2 peri-procedural MI and one ischemia-driven TLR. Between 9- to 24-months, ischemia-driven TLR occurred in 3 additional patients (4.9%) including 1 patient who presented with very late ST after stopping all medications. There were no further TVF between 24- and 36-months., Conclusions: In this multi-center prospective study, the FORTITUDE® BRS was shown to be safe and effective in the treatment of single coronary lesions with low levels of TVF and LLL at 9- and 24-months. It was shown to be clinically safe upto 36-months follow-up., Competing Interests: Declaration of Competing Interest Alaide Chieffo, MD: Proctorship fees from Amaranth Medical Inc. Juan F. Granada, MD: Scientific advisor and equity shareholder Amaranth Medical Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF